Litcius/Paper detail

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Georgina V. Long, Jason J. Luke, Muhammad A. Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E. Gershenwald, Charles H. Yoon, Xi Wu, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Paolo A. Ascierto

2022The Lancet Oncology147 citationsDOI

Topics & Concepts

MedicinePembrolizumabInterim analysisClinical endpointPlaceboInternal medicineAdjuvant therapySurgeryOncologyMelanomaProgression-free survivalRandomized controlled trialChemotherapyCancerPathologyImmunotherapyAlternative medicineCancer researchCutaneous Melanoma Detection and ManagementCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses